TAG:
the clinical laboratory
Attorneys for CAP Say CMS Fee Proposals Illegal
By Joseph Burns | From the Volume XX No. 12 – September 9, 2013 Issue
CEO SUMMARY: In its comments about a proposal to change the way CMS pays for clinical laboratory and pathology services, the College of American Pathologists (CAP) said that CMS is using faulty assumptions. CAP further commented that the CMS proposal to cap physician fee schedule payments…
CMS’ Proposed Lab Rules May Not Fly with Congress
By Joseph Burns | From the Volume XX No. 12 – September 9, 2013 Issue
CEO SUMMARY: Many clinical lab administrators have noticed the new activism at the federal Centers for Medicare Medicaid Services (CMS) when it comes to control of establishing prices for clinical laboratory tests. In this exclusive interview, two long-time advocates for the National Inde…
Lab Landscape Changing as ACOs Get Started
By R. Lewis Dark | From the Volume XX No. 9 – July 8, 2013 Issue
FOR THOSE OF YOU INTERESTED IN HOW the development of accountable care organizations (ACOs) in a community causes a realignment among providers and the clinical laboratories serving them, I offer you the example of Genesis Health System in Davenport, Iowa. As you will read …
Medicare Contractor’s Ruling on MolDx Test Causes Lab to Close
By Joseph Burns | From the Volume XX No. 9 – July 8, 2013 Issue
CEO SUMMARY: On May 14, Predictive Biosciences learned that its Medicare contractor had determined that one of its three molecular tests for bladder cancer was a screening test. It also never got a determination on its other two molecular tests. Because Medicare is half of the lab’s pay…
July 08, 2013 “Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume XX No. 9 – July 8, 2013 Issue
In China, independent clinical laboratories are in a fast-growth mode. That’s the conclusion of RnRMarketResearch in a newly-issued survey of the clinical laboratory testing market in China. It estimates this market segment at US$407 million annually. RnR says that three lab companies meet …
Labs Have New Hurdles as Some Payments Start
By Joseph Burns | From the Volume XX No. 8 – June 17, 2013 Issue
CEO SUMMARY: Some payments are beginning to flow for claims submitted under the new molecular test CPT codes. But there is a new issue. Medicare contractors, Medicaid programs, and private health insurers are deeming certain molecular tests to be medically unnecessary. Th…
OIG Tells CMS It Could Save $910 Million on Lab Test Costs
By Robert Michel | From the Volume XX No. 8 – June 17, 2013 Issue
IT IS ONE MORE POWERFUL SIGN of the changing times. Last week, the Office of the Inspector (OIG) publicly released a study it had done of the prices paid for lab testing and how the Medicare program could use this information to reduce the cost of Part B clinical laboratory testing. It was The W…
Aetna To Lower Lab Test Prices, New Fees Are Effective on July 1
By Robert Michel | From the Volume XX No. 7 – May 28, 2013 Issue
IN RECENT MONTHS, labs are reporting the receipt of letters from Aetna, Inc., announcing that it will pay dramatically less than Medicare prices for many key lab tests. Aetna said that these lower prices will take effect on July 1, 2013. Three examples illustrate the deep fee cuts t…
Much Uncertainty About Pay for Molecular Codes
By Joseph Burns | From the Volume XX No. 7 – May 28, 2013 Issue
CEO SUMMARY: Having gone unpaid since January 1 for the 114 new molecular CPT codes, many clinical labs and pathology groups have stopped running these tests or laid off staff. Some are considering closing their doors. Evidence indicates that certain Medicare contractors are deciding that…
How CMS ‘Mismanaged’ Pricing of Molecular Tests
By Joseph Burns | From the Volume XX No. 5 – April 15, 2013 Issue
CEO SUMMARY: CMS and its contractors had ample opportunity to implement a new reimbursement system but failed to act in a timely manner, stated an expert familiar with the problem. The result is that laboratories, particularly those that have one or two proprietary molecular tests, are be…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized